Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Biotie Therapies
Biotie Therapies
Activities:
Research & Development
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Biotie makes changes to management team
Appoints new Chief Executive, Chief Financial Officer and Chief Medical Officer
Finance
Acorda offers US$363m for Biotie Therapeutics
Expanding its pipeline of drugs to treat Parkinson's Disease
Research & Development
Michael J Fox Foundation to finance Parkinson\'s trials for Biotie Therapies and Cynapsus Therapeutics
Biotie will receive US$2m, while Cynapsus grant is $500,000
Finance
Biotie purchases option to acquire Neurelis
Provides opportunity to develop late-stage product for treatment of epileptic seizures
Research & Development
Biotie terminates agreement to buy Newron
Newron is exploring all options for safinamide
Finance
Biotie Therapies to acquire Newron for €45m
Will continue to focus on CNS drug development
Research & Development
Biotie to acquire Synosia in all-share deal
Will create a CNS drug development company
Subscribe now